Aripiprazole-induced adverse metabolic alterations in polyI:C
neurodevelopmental model of schizophrenia in rats

J 2017

Aripiprazole-induced adverse metabolic alterations in polyI:C neurodevelopmental model of schizophrenia in rats

HORSKÁ, Kateřina, Jana RUDÁ, Eva DRAŽANOVÁ, Michal KARPISEK, Regina DEMLOVÁ et. al.

Basic information

Original name

Aripiprazole-induced adverse metabolic alterations in polyI:C neurodevelopmental model of schizophrenia in rats

Authors

HORSKÁ, Kateřina (203 Czech Republic), Jana RUDÁ (203 Czech Republic, guarantor, belonging to the institution), Eva DRAŽANOVÁ (203 Czech Republic, belonging to the institution), Michal KARPISEK (203 Czech Republic), Regina DEMLOVÁ (203 Czech Republic, belonging to the institution), Tomáš KAŠPÁREK (203 Czech Republic, belonging to the institution) and Hana KOTOLOVÁ (203 Czech Republic)

Edition

Neuropharmacology, Oxford, Pergamon-Elsevier Science LTD, 2017, 0028-3908

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30104 Pharmacology and pharmacy

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 4.249

RIV identification code

RIV/00216224:14110/17:00097232

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1016/j.neuropharm.2017.06.003

UT WoS

000406987300014

Keywords in English

Adipokine; Aripiprazole; Leptin; Lipid profile; PolyI:C; Schizophrenia Wistar rats

Abstract

V originále

Schizophrenia appears to be linked to higher incidence of metabolic syndrome even in the absence of antipsychotic treatment. Atypical antipsychotics substantially differ in their propensity to induce metabolic alterations. Aripiprazole is considered to represent an antipsychotic drug with low risk of metabolic syndrome development. The aim of this study was to evaluate metabolic phenotype of neurodevelopmental polyI:C rat model and assess metabolic effects of chronic aripiprazole treatment with regard to complex neuroendocrine regulations of energy homeostasis. Polyinosinic:polycytidylic acid (polyI:C) was administered subcutaneously at a dose of 8 mg/kg in 10 ml on gestational day 15 to female Wistar rats. For this study 20 polyI:C and 20 control adult male offspring were used, randomly divided into 2 groups per 10 animals for chronic aripiprazole treatment and vehicle. Aripiprazole (5 mg/kg, dissolved tablets, ABILIFY®) was administered once daily via oral gavage for a month. Altered lipid profile in polyI:C model was observed and a trend towards different dynamics of weight gain in polyI:C rats was noted in the absence of significant antipsychotic treatment effect. PolyI:C model was not associated with changes in other parameters i.e. adipokines, gastrointestinal hormones and cytokines levels. Aripiprazole did not influence body weight but it induced alterations in neurohumoral regulations. Leptin and GLP-1 serum levels were significantly reduced, while ghrelin level was elevated. Furthermore aripiprazole decreased serum levels of pro-inflammatory cytokines. Our data indicate dysregulation of adipokines and gastrointestinal hormones present after chronic treatment with aripiprazole which is considered metabolically neutral in the polyI:C model of schizophrenia.

Links

LM2015090, research and development project

Name: Český národní uzel Evropské sítě infrastruktur klinického výzkumu (Acronym: CZECRIN)

Investor: Ministry of Education, Youth and Sports of the CR

MUNI/A/1063/2016, interní kód MU

Name: Experimentální a translační farmakologický výzkum a vývoj

Investor: Masaryk University, Category A

Citovat

HORSKÁ, Kateřina, Jana RUDÁ, Eva DRAŽANOVÁ, Michal KARPISEK, Regina DEMLOVÁ, Tomáš KAŠPÁREK and Hana KOTOLOVÁ. Aripiprazole-induced adverse metabolic alterations in polyI:C neurodevelopmental model of schizophrenia in rats. Neuropharmacology. Oxford: Pergamon-Elsevier Science LTD, 2017, vol. 123, 1 September 2017, p. 148-158. ISSN 0028-3908. Available from: https://dx.doi.org/10.1016/j.neuropharm.2017.06.003.

@article{1386067,
   author = {Horská, Kateřina and Rudá, Jana and Dražanová, Eva and Karpisek, Michal and Demlová, Regina and Kašpárek, Tomáš and Kotolová, Hana},
   article_location = {Oxford},
   article_number = {1 September 2017},
   doi = {http://dx.doi.org/10.1016/j.neuropharm.2017.06.003},
   keywords = {Adipokine; Aripiprazole; Leptin; Lipid profile; PolyI:C; Schizophrenia Wistar rats},
   language = {eng},
   issn = {0028-3908},
   journal = {Neuropharmacology},
   title = {Aripiprazole-induced adverse metabolic alterations in polyI:C neurodevelopmental model of schizophrenia in rats},
   url = {https://www.sciencedirect.com/science/article/pii/S0028390817302733?via%3Dihub},
   volume = {123},
   year = {2017}
}

TY  - JOUR
ID  - 1386067
AU  - Horská, Kateřina - Rudá, Jana - Dražanová, Eva - Karpisek, Michal - Demlová, Regina - Kašpárek, Tomáš - Kotolová, Hana
PY  - 2017
TI  - Aripiprazole-induced adverse metabolic alterations in polyI:C neurodevelopmental model of schizophrenia in rats
JF  - Neuropharmacology
VL  - 123
IS  - 1 September 2017
SP  - 148-158
EP  - 148-158
PB  - Pergamon-Elsevier Science LTD
SN  - 00283908
KW  - Adipokine
KW  - Aripiprazole
KW  - Leptin
KW  - Lipid profile
KW  - PolyI:C
KW  - Schizophrenia Wistar rats
UR  - https://www.sciencedirect.com/science/article/pii/S0028390817302733?via%3Dihub
L2  - https://www.sciencedirect.com/science/article/pii/S0028390817302733?via%3Dihub
N2  - Schizophrenia appears to be linked to higher incidence of metabolic syndrome even in the absence of antipsychotic treatment. Atypical antipsychotics substantially differ in their propensity to induce metabolic alterations. Aripiprazole is considered to represent an antipsychotic drug with low risk of metabolic syndrome development. The aim of this study was to evaluate metabolic phenotype of neurodevelopmental polyI:C rat model and assess metabolic effects of chronic aripiprazole treatment with regard to complex neuroendocrine regulations of energy homeostasis. Polyinosinic:polycytidylic acid (polyI:C) was administered subcutaneously at a dose of 8 mg/kg in 10 ml on gestational day 15 to female Wistar rats. For this study 20 polyI:C and 20 control adult male offspring were used, randomly divided into 2 groups per 10 animals for chronic aripiprazole treatment and vehicle. Aripiprazole (5 mg/kg, dissolved tablets, ABILIFY®) was administered once daily via oral gavage for a month. Altered lipid profile in polyI:C model was observed and a trend towards different dynamics of weight gain in polyI:C rats was noted in the absence of significant antipsychotic treatment effect. PolyI:C model was not associated with changes in other parameters i.e. adipokines, gastrointestinal hormones and cytokines levels. Aripiprazole did not influence body weight but it induced alterations in neurohumoral regulations. Leptin and GLP-1 serum levels were significantly reduced, while ghrelin level was elevated. Furthermore aripiprazole decreased serum levels of pro-inflammatory cytokines. Our data indicate dysregulation of adipokines and gastrointestinal hormones present after chronic treatment with aripiprazole which is considered metabolically neutral in the polyI:C model of schizophrenia.
ER  -

HORSKÁ, Kateřina, Jana RUDÁ, Eva DRAŽANOVÁ, Michal KARPISEK, Regina DEMLOVÁ, Tomáš KAŠPÁREK and Hana KOTOLOVÁ. Aripiprazole-induced adverse metabolic alterations in polyI:C neurodevelopmental model of schizophrenia in rats. \textit{Neuropharmacology}. Oxford: Pergamon-Elsevier Science LTD, 2017, vol.~123, 1 September 2017, p.~148-158. ISSN~0028-3908. Available from: https://dx.doi.org/10.1016/j.neuropharm.2017.06.003.

Detailed Information on Publication Record